Delcath Systems Competitors, Revenue, Alternatives and Pricing
Overview
Employee Data
- Delcath Systems has 36 Employees.
- Delcath Systems currently has 1 job openings.
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
Advertise Here | ||||||
#1 | N/A | 686 | N/A | N/A | - | N/A |
#2 | $372.5M | 1853 | N/A | N/A | - | N/A |
#3 | $38.2M | 190 | N/A | N/A | - | N/A |
#4 | N/A | 36 | N/A | N/A | - | N/A |
#5 | $22.1M | 110 | 24% | N/A | - | N/A |
#6 | $581.3M | 2892 | N/A | N/A | - | N/A |
#7 | $13.5M | 67 | N/A | N/A | - | N/A |
#8 | $43.4M | 216 | N/A | N/A | - | N/A |
#9 | $15.1M | 75 | 10% | N/A | - | N/A |
#10 | $47.4M | 236 | 15% | N/A | 4.2/5 | N/A |
What Is Delcath Systems?
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)-is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers. In the United States, the Melphalan/HDS system is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). The Melphalan/HDS system has not been approved for sale in the United States. In Europe
keywords:N/A36
Number of Employees
N/A
Revenue (est)
1
Current Jobs
N/A
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
N/A
Type
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
#1 | $5.2M | 36 | 33% | N/A | - | N/A |
#2 | N/A | 36 | N/A | N/A | - | N/A |
#3 | $8.2M | 36 | 33% | N/A | - | N/A |
#4 | $8.2M | 36 | 9% | $876.7M | - | N/A |
#5 | N/A | 36 | 24% | N/A | - | N/A |